Date | Price Target | Rating | Analyst |
---|---|---|---|
10/20/2023 | Peer Perform | Wolfe Research | |
1/6/2023 | $28.00 | Equal-Weight → Underweight | Morgan Stanley |
9/8/2022 | Neutral | BTIG Research | |
8/1/2022 | $33.00 | Equal-Weight | Morgan Stanley |
6/21/2022 | $25.00 | Underperform | BofA Securities |
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SC 13G - Embecta Corp. (0001872789) (Subject)
4 - Embecta Corp. (0001872789) (Issuer)
Embecta Corp (NASDAQ:EMBC), a manufacturer of disposable insulin pen needles and syringes, is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson and Company (NYSE:BDX). The medical technology company, which supplies approximately 8 billion syringes and needle pens annually across more than 100 countries, has engaged advisers from Centerview Partners to explore a sale. Embecta’s share price has plummeted nearly 70% since its April 2022 spin-off, leaving the Nasdaq-listed firm valued at $2.1 billion. The decline is attributed to several factors, including the impact of GLP-1 drugs such as Novo Nord
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
https://www.ft.com/content/4aa65f0f-dcdf-4849-bd87-b81b23961fc1Diabetes device maker Embecta has hired advisers to explore a possible sale, following two years of lacklustre share price performance after the medical technology business was spun out of health tech giant Becton Dickinson. Embecta, which is the world's largest maker of disposable insulin pen needles and syringes for diabetics, tapped advisers from Centerview Partners in recent months to guide a possible sale of the business, according to two people familiar with the matter. The medtech business, which sells about 8bn syringes and needle pens annually to more than 100 countries worldwide, could be an attractive takeover target f
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
3/A - Embecta Corp. (0001872789) (Issuer)
While 9 out of 10 people with diabetes are living with T2D, many of the automated insulin delivery solutions currently on the market were designed for people living with T1D.300-unit insulin reservoir is more suitable for people with T2D who are interested in moving from multiple daily injections (MDI) to pump therapy, based on an average daily dose of 95.9 units of insulin.1 PARSIPPANY, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery sys
PARSIPPANY, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events: 2024 Wells Fargo Healthcare Conference • Management will host one-on-one investor meetings on Wednesday, September 4, 2024, at the Encore Boston Harbor Hotel in Boston. 2024 Morgan Stanley 22nd Annual Global Healthcare Conference • Management will host a fireside session on Thursday, September 5, 2024, at 2:35 p.m. Eastern Time (ET) at the Marriott Marquis in New York. Audio webcasts of the presentations will be accessible under the "News & E
PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2024. "During the third quarter our business performed in alignment with our expectations. We generated strong gross, operating and EBITDA margins even as revenue was impacted by the expected timing of customer orders that had positively impacted our second quarter results," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "From a year-to-date perspective, our financial results demonstrated the contin
8-K - Embecta Corp. (0001872789) (Filer)
10-Q - Embecta Corp. (0001872789) (Filer)
8-K - Embecta Corp. (0001872789) (Filer)
Wolfe Research initiated coverage of Embecta Corp. with a rating of Peer Perform
Morgan Stanley downgraded Embecta Corp. from Equal-Weight to Underweight and set a new price target of $28.00
BTIG Research initiated coverage of Embecta Corp. with a rating of Neutral
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the
Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply
PARSIPPANY, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company, announced it will ring the Nasdaq opening bell today, in recognition of National Diabetes Awareness Month in November. The coming year is also a time to celebrate the company's heritage in providing solutions to people living with diabetes, including 100 years since the development and launch of the first syringe dedicated to insulin delivery. Advocacy and professional groups including the Association of Diabetes Care & Education Specialists (ADCES), Beyond Type 1, Beyond Type 2, Camp Nejeda, Children with Diabetes, Diabetes Education and Camping Association (DECA),
PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2024. "During the third quarter our business performed in alignment with our expectations. We generated strong gross, operating and EBITDA margins even as revenue was impacted by the expected timing of customer orders that had positively impacted our second quarter results," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "From a year-to-date perspective, our financial results demonstrated the contin
PARSIPPANY, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024 to stockholders of record at the close of business on August 27, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels
PARSIPPANY, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal third quarter 2024 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, Aug 9, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on Aug 9, 2024, via the embecta investor rela